To identify drugs that can target Pten/p53-deficient TNBCs with high AKT pathway activity, weperformed a kinome drug screen (238 compounds targeting 154 different kinases; 3 μM;alamar blue assay) on four PtenΔf:p53Δf tumor cultures, eachestablished from a distinct MMTV-Cre:Ptenf/f:p53f/f mammary tumor. This evidence concerns the gene TP53 and breast cancer.